BUHLMANN CORP

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

June 10, 2019
BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Read more

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

August 21, 2018

Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663.

Read more

The Advantages of an Immunoturbidimetric Assay for Measuring Calprotectin in Fecal Samples

March 13, 2018

An immunoturbidimetric assay (or particle-enhanced turbidimetric immunoassay (PETIA)) for measuring Calprotectin is the fastest solution in the market with the shortest time to first result regardless of using sample batches or random access.

Read more

Fecal Calprotectin Measurement is a Marker of Short-Term Clinical Outcome and Presence of Mucosal Healing in Patients with Inflammatory Bowel Disease

December 19, 2017
BÜHLMANN fCAL® ELISA: A.Kostas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology; November 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387. Highlights from this Publication “In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a strong
Read more